<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04278885</url>
  </required_header>
  <id_info>
    <org_study_id>DEALZ-2019-01</org_study_id>
    <nct_id>NCT04278885</nct_id>
  </id_info>
  <brief_title>Lanadelumab in FXII-associated Cold Autoinflammatory Syndrome (FACAS)</brief_title>
  <acronym>LANA-FXII</acronym>
  <official_title>Factor XII-associated Cold Autoinflammatory Syndrome (FACAS) Linked to Kallikrein-kinin Pathology: Proof of Concept Treatment With Lanadelumab (DX-2930)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Charite University, Berlin, Germany</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Shire International GmbH</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Charite University, Berlin, Germany</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase 2, exploratory, proof-of-concept, single-center, open-label pilot study to
      assess the effects and safety of Lanadelumab in patients with FXII-associated cold
      autoinflammatory syndrome (FACAS).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Factor XII is a serine protease with diverse functions that participates in coagulation,
      fibrinolysis, complement and contact system activation. So far, mutations in the factor XII
      gene were linked to the rare coagulation disorder Hagemann factor deficiency and hereditary
      angioedema (FXII-HAE).

      The investigators recently identified a novel FXII mutation in a 4-generation family with
      profound contact system activation and an autoinflammatory clinical phenotype.

      Lanadelumab is a specific kallikrein Inhibitor that is known to prevent clinical symptoms and
      contact system activation in hereditary angioedema.

      This study aims at assessing the clinical effects and safety of Lanadelumab in patients with
      FXII-associated cold autoinflammatory syndrome (FACAS).
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">October 2020</start_date>
  <completion_date type="Anticipated">November 2021</completion_date>
  <primary_completion_date type="Anticipated">June 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>exploratory, proof-of-concept, single-center, open-label pilot study</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in total disease activity score as assessed by daily health assessment form (DHAF) questionnaire following lanadelumab treatment</measure>
    <time_frame>weeks 9 to 12 compared to weeks -4 to -1 (baseline)</time_frame>
    <description>Patient-reported total disease activity is assessed by a disease-specific daily health assessment form (FXII-associated Cold autoinflammatory Syndrome daily Health assessment form; FACAS-DHAF) grading the severity of 5 key symptoms of FACAS: urticarial rash, fatigue, chills/fever, arthralgia and headache (scale 0=no symptoms to 50=max. of symptoms).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in urticarial rash disease activity score as assessed by daily health assessment form (DHAF) questionnaire following lanadelumab treatment</measure>
    <time_frame>weeks 9 to 12 and weeks 24 to 28, each compared to weeks -4 to -1 (baseline)</time_frame>
    <description>Patient-reported urticarial rash disease activity is assessed by a disease-specific daily health assessment form (FXII-associated Cold autoinflammatory Syndrome daily Health assessment form; FACAS-DHAF; scale 0=no symptoms to 10=max. of symptoms)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in fatigue disease activity score as assessed by daily health assessment form (DHAF) questionnaire following lanadelumab treatment</measure>
    <time_frame>weeks 9 to 12 and weeks 24 to 28, each compared to weeks -4 to -1 (baseline)</time_frame>
    <description>Patient-reported fatigue disease activity is assessed by a disease-specific daily health assessment form (FXII-associated Cold autoinflammatory Syndrome daily Health assessment form; FACAS-DHAF; scale 0=no symptoms to 10=max. of symptoms)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in chills/fever disease activity score as assessed by daily health assessment form (DHAF) questionnaire following lanadelumab treatment</measure>
    <time_frame>weeks 9 to 12 and weeks 24 to 28, each compared to weeks -4 to -1 (baseline)</time_frame>
    <description>Patient-reported chills/fever disease activity is assessed by a disease-specific daily health assessment form (FXII-associated Cold autoinflammatory Syndrome daily Health assessment form; FACAS-DHAF;scale 0=no symptoms to 10=max. of symptoms)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in arthralgia disease activity score as assessed by daily health assessment form (DHAF) questionnaire following lanadelumab treatment</measure>
    <time_frame>weeks 9 to 12 and weeks 24 to 28, each compared to weeks -4 to -1 (baseline)</time_frame>
    <description>Patient-reported arthralgia disease activity is assessed by a disease-specific daily health assessment form (FXII-associated Cold autoinflammatory Syndrome daily Health assessment form; FACAS-DHAF; scale 0=no symptoms to 10=max. of symptoms)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in headache disease activity score as assessed by daily health assessment form (DHAF) questionnaire following lanadelumab treatment</measure>
    <time_frame>weeks 9 to 12 and weeks 24 to 28, each compared to weeks -4 to -1 (baseline)</time_frame>
    <description>Patient-reported headache disease activity is assessed by a disease-specific daily health assessment form (FXII-associated Cold autoinflammatory Syndrome daily Health assessment form; FACAS-DHAF; scale 0=no symptoms to 10=max. of symptoms)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in total disease activity score as assessed by daily health assessment form (DHAF) questionnaire following lanadelumab Treatment over Long-term use</measure>
    <time_frame>weeks 24 to 28 compared to weeks -4 to -1 (baseline)</time_frame>
    <description>Patient-reported total disease activity is assessed by a disease-specific daily health assessment form (FXII-associated Cold autoinflammatory Syndrome daily Health assessment form; FACAS-DHAF; scale 0=no symptoms to 50=max. of symptoms</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in inflammation markers following lanadelumab Treatment</measure>
    <time_frame>from Baseline to week 12 and week 28</time_frame>
    <description>Assessment of CRP levels</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in inflammation markers following lanadelumab Treatment</measure>
    <time_frame>from Baseline to week 12 and week 28</time_frame>
    <description>Assessment of ESR levels</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in inflammation markers following lanadelumab Treatment</measure>
    <time_frame>from Baseline to week 12 and week 28</time_frame>
    <description>Assessment of SAA levels</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in inflammation markers following lanadelumab Treatment</measure>
    <time_frame>from Baseline to week 12 and week 28</time_frame>
    <description>Assessment of S100 A8/9 levels</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in dermatology-specific quality-of-life following lanadelumab Treatment</measure>
    <time_frame>from Baseline to week 12 and week 28</time_frame>
    <description>assessed by Dermatology Life Quality Index (DLQI); scale 0=no impairment to 30=max. impairment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in generic Health-related quality-of-life</measure>
    <time_frame>from Baseline to week 12 and week 28</time_frame>
    <description>assessed by 36-Item Short Form Health Survey (SF-36); scale 0=max. impairment to 100=no impairment (best Quality of life)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of of Treatment-emergent adverse Events, abnormal physical examination, abnormal Routine safety laboratory assessments, abnormal vital signs (safety and tolerability)</measure>
    <time_frame>from Baseline to end of study (week 36 follow-up)</time_frame>
    <description>Safety of lanadelumab Treatment is assessed by physical examination, routine safety laboratory assessments, vital signs, and adverse Event reporting.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in physician global assessment following lanadelumab Treatment as assessed by verbal rating scale</measure>
    <time_frame>from Baseline to week 12 and week 28</time_frame>
    <description>Verbal Rating scale assesses overall Symptoms from 0-10 (0=no symptoms; 10=very severe symptoms)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes of plasma levels of potential biomarkers following Lanadelumab treatment</measure>
    <time_frame>from Baseline to week 28</time_frame>
    <description>Potential biomarkers include Plasma FXII Levels</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes of plasma levels of potential biomarkers following Lanadelumab treatment</measure>
    <time_frame>from Baseline to week 28</time_frame>
    <description>Potential biomarkers include Plasma prekallikrein Levels</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes of plasma levels of potential biomarkers following Lanadelumab treatment</measure>
    <time_frame>from Baseline to week 28</time_frame>
    <description>Potential biomarkers include Plasma cHMWK Levels</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes of plasma levels of potential biomarkers following Lanadelumab treatment</measure>
    <time_frame>from Baseline to week 28</time_frame>
    <description>Potential biomarkers include IL-1ÃŸ release from donor PBMCs</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">3</enrollment>
  <condition>Hereditary Autoinflammatory Disease</condition>
  <arm_group>
    <arm_group_label>Lanadelumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lanadelumab</intervention_name>
    <description>300mg Lanadelumab s.c. administration every 2 weeks</description>
    <arm_group_label>Lanadelumab</arm_group_label>
    <other_name>DX-2930</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adults (18 years or older)

          -  Documented FXII-associated autoinflammatory disorder (FACAS) by positive genetic
             analysis result

          -  Clinical symptoms of cold-associated wheals, arthralgia, headache, fatigue (FACAS)

          -  Able to read, understand and willing to sign the informed consent form and abide with
             study procedures

          -  Males and females who are fertile and sexually active must adhere to contraception
             requirements for the duration of the study as follows:

          -  Females of childbearing potential must agree to be abstinent or else use any two of
             the following medically acceptable forms of contraception from the screening period
             through 30 days after the final study visit: progestin-only oral contraceptive, condom
             with or without spermicidal jelly, diaphragm or cervical cap with spermicidal jelly,
             or intra-uterine device (IUD, all types). Female participants whose male partner has
             had a vasectomy must agree to use one additional form of medically acceptable
             contraception.

          -  Females of non-childbearing potential, defined as surgically sterile (status post
             hysterectomy, bilateral oophorectomy, or bilateral tubal ligation) or post-menopausal
             for at least 12 months do not require contraception during the study.

          -  Males, including males who are surgically sterile (post vasectomy), with female
             partners of childbearing potential must agree to be abstinent or else use a medically
             acceptable form of contraception from the screening period through 60 days after the
             last IMP injection.

        Exclusion Criteria:

          -  1. Any other forms of urticaria or angioedema not related to genetic mutations within
             the FXII gene 2. Concurrent/ongoing treatment with biologics or recent treatment (less
             than 5 half-lives) 3. Concurrent/ongoing treatment with anakinra within 7 days prior
             to screening, with canakinumab within 100 days prior to screening 4.
             Concurrent/ongoing treatment with oral/parenteral corticosteroids greater than 10 mg/d
             within 2 weeks prior to screening 5. Concurrent/ongoing treatment with other
             immunosuppressives within 4 weeks or 5 half-lives prior to screening, whichever is
             longer 6. Treatment with a live (attenuated) virus vaccine within 4 weeks prior to
             Baseline visit 7. Exposure to angiotensin-converting enzyme (ACE) inhibitors or any
             estrogen-containing medications with systemic absorption (such as oral contraceptives
             or hormonal replacement therapy) within 4 weeks prior to screening.

             8. Use of prophylactic therapy with C1-INH, attenuated androgens, or antifibrinolytics
             within 2 weeks prior to the start of the treatment period (Day 0).

             9. Any of the following liver function test abnormalities:

               -  alanine aminotransferase (ALT) &gt; 3x upper limit of normal, or

               -  aspartate aminotransferase (AST) &gt; 3x upper limit of normal, or

               -  total bilirubin &gt; 2x upper limit of normal (unless the bilirubin elevation is a
                  result of Gilbert's Syndrome).

                  10. Pregnancy or breastfeeding. 11. Subject has any condition that, in the
                  opinion of the Investigator or Sponsor, may compromise their safety or
                  compliance, preclude successful conduct of the study, or interfere with
                  interpretation of the results (e.g., history of substance abuse or dependence, a
                  significant pre-existing illness or other major comorbidity that the Investigator
                  considers may confound the interpretation of study results).

                  12. Significant medical condition rendering the patient immunocompromised or not
                  suitable for a clinical trial.

                  13. Enrollment in another investigational treatment or device study or use of an
                  investigational agent, or less than 4 weeks or 5 half-lives, whichever is longer,
                  since end of another investigational device or drug trial.

                  14. Patients with known hypersensitivity to any constituent of the products of
                  lanadelumab.

                  15. Dementia, altered mental status, or any psychiatric condition, or stay in an
                  institution further to an official or court order that would prohibit the
                  understanding or rendering of informed consent or participation in the study.

                  16. Subjects who are study site employees, or immediate family members of a study
                  site or sponsor employee.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>120 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Karoline Krause, PD Dr. med.</last_name>
    <phone>+4930450518336</phone>
    <email>karoline.krause@charite.de</email>
  </overall_contact>
  <location>
    <facility>
      <name>Charite University, Berlin, Germany</name>
      <address>
        <city>Berlin</city>
        <zip>10117</zip>
        <country>Germany</country>
      </address>
    </facility>
    <contact>
      <last_name>Krause Karoline, PD Dr. med.</last_name>
      <phone>004930450518336</phone>
      <email>karoline.krause@charite.de</email>
    </contact>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>February 13, 2020</study_first_submitted>
  <study_first_submitted_qc>February 19, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">February 20, 2020</study_first_posted>
  <last_update_submitted>February 19, 2020</last_update_submitted>
  <last_update_submitted_qc>February 19, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 20, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Charite University, Berlin, Germany</investigator_affiliation>
    <investigator_full_name>Karoline Krause</investigator_full_name>
    <investigator_title>Ass. Professor</investigator_title>
  </responsible_party>
  <keyword>FXII-associated cold autoinflammatory syndrome (FACAS)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hereditary Autoinflammatory Diseases</mesh_term>
    <mesh_term>Familial Mediterranean Fever</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

